Sean Kim, MD
Retina Specialist · Baltimore, MDNPI 1588124697
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 43.0% of the total. Reporting peaked in 2024 at $1,491 and has fallen 70.9% since, to $434 in 2025. That places this record below the midpoint for retina specialist clinicians in MD, where the typical reported total is $3,416.
Across 32 payments — averaging $107.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Alcon$1K
- Genentech USA, Inc.$179
- AbbVie$130
- Regeneron Healthcare Solutions, Inc.$101
- ANI Pharmaceuticals, Inc.$66
- plus $67 from 2 others
What the payments were for
- Travel & lodging$1,84954%
- Food & beverage$1,49643%
- Education$1003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 14 | $1,480 |
| Alcon | 6 | $1,422 |
| Genentech USA, Inc. | 2 | $179 |
| AbbVie(2 entities) | 2 | $130 |
| Regeneron Healthcare Solutions, Inc. | 3 | $101 |
| ANI Pharmaceuticals, Inc. | 2 | $66 |
| Apellis Pharmaceuticals, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$989
- VABYSMO$146
- STELLARIS$137
- Constellation$132
How this compares
$3,445 in reported general payments places this provider in the 50th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 42 | $1,688 |
| Difluprednate | 11 | $728 |
| Ketorolac Tromethamine | 19 | $698 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $608 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 18 | $419 |
| Latanoprost | 32 | $359 |
| Brimonidine Tartrate | 24 | $119 |
| Prednisone | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Baltimore
- Michael ElmanBaltimore$27K
- Sidney SchechetBaltimore$23K
- Lisa SchocketBaltimore$7K
- Heather TamezBaltimore$4K
- Daniel BrillBaltimore$3K
- David DaoBaltimore$3K
- Christina AntonopoulosBaltimore$304
- Kenneth TaubenslagBaltimore$150
- Rohit LakhanpalOwings Mills$168K
- Brian DoChevy Chase$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.